One of our final interviews was with Mark Womack, CEO of BioCina, a CDMO specializing in the development and production of biotherapeutics. Recently expanding into Australia, BioCina was drawn by the country’s supportive government policies, strong infrastructure, and university-led initiatives in clinical trials. Mark shares BioCina’s plans to add mammalian production capabilities to their existing microbial, plasmid DNA, and mRNA offerings, highlighting the company’s growth and Australia’s expanding role in global biopharma innovation.
